Moreover, patients with lower baseline IL-6 levels responded more favorably to PD-1/PD-L1 inhibitors in NSCLC, showcasing elevated ORR and prolonged OS and PFS. This evidence concerns the gene IL6 and non-small cell lung carcinoma.